Adaptive Biotechnologies: Why Insider Selling Casts a Shadow on Its High-Flying Stock

Related Articles

Is Insider Selling a Red Flag for Adaptive Biotechnologies (ADPT) Investors

6 months ago

Insider Selling Casts a Shadow on PubMatic's AI-Driven Growth Story

1 months ago

The Shadow of Insider Selling

1 months ago

AIAI Holdings: Insider Selling Casts a Shadow Over Its AI Ambitions

2 months ago

Category

You may also like

Stock News•1 months ago

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Adaptive Biotechnologies (ADPT) is spinning off Immune Medicine to become a pure-play MRD diagnostics firm. MRD revenue grew 49% YoY, sequencing gross margins exceeded 70%, and adjusted EBITDA margin ...

ADPT

Share

Stock News•1 months ago

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Adaptive Biotechnologies (ADPT) may report negative earnings next week, as it lacks the typical combination for an earnings beat, per the article's preview.

ADPT

Share

Stock News•1 months ago

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

An Adaptive Biotechnologies insider sold ~386K shares for $8.5M on July 2, 2026, after the stock's 85% run-up.

ADPT

Share